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ABSTRACT   
Stroke is a major cause of morbidity and mortality worldwide. Despite the intensive search 
for new therapies, hundreds of agents targeting various pathophysiological mechanisms have 
failed clinical trials, and the thrombolytic agent tissue plasminogen activator is currently the 
only FDA-approved medication for the treatment of acute ischaemic stroke (AIS). The 
immune system is involved in all stages of stroke, from the pathogenesis of risk factors to 
neurotoxicity, to tissue remodelling and repair. There is a bi-directional interaction between 
the brain and the immune system, with stroke-induced immunosuppression and subsequent 
infection a principal source of patient mortality. Newer work also points to a role for the gut 
microbiota in the immune response to stroke, while clinical sequelae such as dementia might 
now also be explained in immune terms. However, the exact roles of innate and adaptive 
components have not been fully elucidated, with studies reporting both detrimental and 
beneficial functions. Time is a key determinant in defining whether immunity and 
inflammation are neuroprotective or neurotoxic. The local inflammatory milieu also has a 
clear influence on many proposed treatments. This review examines the individual 




Stroke, a cerebrovascular disease of which 87% are ischaemic in nature, remains a major 
cause of morbidity and mortality worldwide1, 2. It stands as the most common cause of 
acquired disability, with roughly 100 million disability-adjusted life years (DALYs) lost 
annually by survivors 1. However, despite the intensive search for new therapeutic strategies, 
the options for acute ischaemic stroke (AIS) treatment are limited; intravenous recombinant 
tissue plasminogen activator (rtPA) is the only FDA-approved medication3. tPA can restore 
perfusion to the brain via thrombolysis and thereby prevent cell death in the hypoperfused but 
potentially salvageable area known as the ischaemic penumbra. However, beyond a 
therapeutic window of 4.5 hours, the benefits of tPA are outweighed by its risks, with the 
incidence of haemorrhagic transformation increasing dramatically 2. Alternatives to 
thrombolysis include intra-arterial thrombectomy with medical devices, but these are not 
without their own complications and limitations 3.   
Over the last few decades, neuroprotection has been the main focus of proposed treatments in 
AIS. To date however, the field of brain-protective medicines remains a therapeutic 
graveyard, with over 1000 different molecules buried across hundreds of failed clinical trials 
4. Yet, despite the poor clinical translation, both animal and human studies show that the 
immune response plays a pivotal and multi-faceted role in central nervous system (CNS) 
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Several reviews have examined the intricate connection between the immune system and 
CNS in stroke 5-9. To the best of our knowledge, however, none have examined the full 
spectrum of immune targets and potential therapies. The aim of this review, therefore, is to 
discuss not only the contribution of the immune system to disease initiation, progression and 
resolution in stroke, but also the most promising avenues for future stroke immunotherapy.  
 
THE IMMUNE RESPONSE TO ACUTE ISCHAEMIC STROKE    
Stroke Onset 
Following the onset of brain ischaemia, a sequence of events involving the CNS, its 
vasculature, the blood, and lymphoid organs is invoked. Ischaemic stroke starts in the blood 
vessels, where arterial occlusion results in hypoxia, reactive oxidative species (ROS) 
production, and changes in shear stress across the lumen wall 10, 11. The coagulation cascade 
is triggered, resulting in microvascular occlusion. Platelet aggregation is exacerbated by the 
concomitant fall in the bioavailability of nitrous oxide (NO). The combined effect of 
oxidative stress, inflammatory mediators (e.g. IL-1, TNF-α), downregulated endothelial 
junction proteins and upregulated leukocyte- or vascular-derived proteases increases blood 
brain barrier (BBB) permeability. A critical point is reached if these processes causes 
detachment of endothelial cells from the basement membrane, at which stage the unimpeded 
entry of free water and serum into the brain leads to haemorrhage 6.  
Endothelial cell-derived prostaglandins and chemoattractant also drive leukocyte entry into 
the infarct site 6. The infiltration of neutrophils, macrophages, and other leukocytes is further 
promoted by the activation of high-avidity integrin molecules on the leukocyte surface and 
the upregulated expression of corresponding ligands on the endothelium e.g. vascular cell 
adhesion molecule-1 (VCAM-1) and intracellular adhesion molecule-1(ICAM-1). Activated 
leukocytes produce ROS, proteolytic enzymes, leukotrienes, cytokines, platelet-activating 
factor which promote vasoconstriction, platelet aggregation, and further neurotoxicity 10. In 
the perivascular space, activated macrophages secrete a host of pro-inflammatory cytokines, 
while mast cell degranulation results in the release of histamine, proteases and TNF-α, further 
degrading BBB integrity.  
While all these processes are occurring in the blood vessels and perivascular spaces, 
ischaemia also impacts the brain parenchyma. Hypoperfusion causes an immediate 
deprivation of glucose and oxygen, leading to a fall in ATP production A series of 
interconnected cytoplasmic and nuclear events then begins (bioenergetic failure, 
acidotoxicity, excitotoxicity, oxidative stress and inflammation), causing neuronal cell death 
11. The release of danger/damage-associated molecular patterns (DAMPs) from dying and 
dead neurons precipitates a new phase of the inflammatory response 8. Activation of pattern-
recognition receptors (PRRs) leads to the production of IL-1β and TNF-α. An inflammatory 
environment emerges as a result, containing IL-17, perforin, granzyme, and increasing 
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The adaptive arm of the immune response is activated as early as 24 hours post-stroke 8. It is 
widely accepted that T cells have a damaging effect in this acute phase of stroke, as mice 
lacking T cells showed smaller infarct size and improved functional outcome 12. The fact that 
this neuroprotection is abolished by the re-introduction of T cells further corroborates the 
view that T lymphocytes are involved in stroke pathophysiology. Natural killer (NK) cells 
and CD4+ T cell subtypes exacerbate neurotoxicity in the early stages of stroke in an antigen-
independent manner, possibly via the secretion of several cytokines, including IFN-γ and  IL-
17 6. Infiltrated γδ and CD8+ T cells mediate further neuronal cytotoxicity. Antigen-specific 
T cells, on the other hand, only contribute later to stroke pathophysiology, participating in 
autoimmune or tolerance reactions in a manner largely dependent on whether they are 
skewed towards a more damaging (T helper 1 (TH1), T helper 17 (TH17)) or protective (T 
helper 2 (TH2), T regulatory (Treg)) phenotype 
9. Lastly, B cells can produce antibodies 
against brain-derived molecules, resulting in further neuronal damage in the weeks following 
disease onset and possibly leading to clinical stroke sequelae such as dementia 13.  
Initial inflammation is self-limiting and ultimately gives way to structural remodelling and 
functional reorganisation. The end of the acute phase is characterised by three processes 10: 1) 
removal of dead cells/tissue debris, 2) creation of an anti-inflammatory milieu, and 3) 
production of pro-survival factors.  
The processes of repair and reconstruction, which involves neuronal sprouting, angiogenesis, 
neurogenesis, and alteration to the cellular matrix, are carried out in concert by many cells 
types, ranging from immune cells to neurons and astrocytes. Together, these cells produce 
growth factors and proteases, allowing for re-modelling of the ischaemic site 10.   
 
Stroke-induced immunosuppression 
The relationship between the immune system and central nervous system operates 
bidirectionally. In the early stages of stroke, activation of primary and secondary lymphoid 
organs produces a systemic inflammatory response, a transient 24-hour period in which 
circulating levels of cytokines, chemokines and pro-inflammatory mediators are elevated. 
This early inflammatory response is followed two days post-stroke by a second phenomenon 
termed stroke-induced immunodepression (SIID) 14. SIID is hallmarked by lymphopenia, 
splenic atrophy and increased levels of anti-inflammatory cytokines17. Mechanistically, the 
CNS elicits these changes in immune function through complex humoral and neural 
pathways, which include the sympathetic nervous system (SNS), the vagus nerve, and the 
hypothalamic-pituitary-adrenal (HPA) axis. It is unclear whether the nature of the immune 
response after stroke is influenced by brain infarct location, but the extent of brain damage 
does seem to be a crucial factor in SIID 15.  
Large studies have estimated that approximately 30% of stroke patients contract post-stroke 
infections, the most prevalent of which are pneumonia and urinary tract infections 16. The 
most commonly implicated microorganisms include Staphylococcus aureus, Klebsiella 
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cases occur within the first two days after stroke, while almost all others are seen within a 
week. Indeed, a prospective study of stroke patients showed that 75% of post-stroke 
infections are diagnosed within three days of hospitalization, indicating a large role for SIID 
and not poor patient care 16.  
Although SIID is detrimental with respect to resulting post-stroke infections, it may 
teleologically have a protective function, whereby downregulation of the peripheral immune 
response shields the CNS from autoimmunity. Blood-brain barrier breakdown during the 
acute stage of stroke allows almost unfettered access of immune cells to the CNS, and 
antigens normally sequestered in the brain become visible, possibly for the first time. 
Evidence suggests these antigens can enter the circulation and be presented to lymphocytes in 
lymph nodes within hours of experimental stroke, thereby inducing autoreactive T and B cells 
17. While the phenomenon of stroke-induced immunosuppression could prevent such 
autoimmune responses, there are mitigating factors which help to subvert it, including 
infection. Autoreactive immune responses are promoted in two main ways 8: 
• Bacterial components activate Toll-like Receptors (TLRs) on Antigen-Presenting 
Cells (APCs) resulting in overall increased antigen presentation and immune 
stimulation.   
• Increased levels of IFN-γ provide an inflammatory milieu which favours the induction 
of TH1 type responses  
The overall consequences of SIID therefore remains unclear, with the net outcome likely to 
differ significantly between patients. On the contrary, the deleterious effects of infections at 
all stages of stroke are beyond question. As such, strategies which aim to reduce their 
prevalence (including prophylactic antibiotics, hygiene precautions, scoring algorithms for 
infection diagnosis, suction or modified diets to prevent aspiration, and antiseptic-
impregnated catheters) are sure to receive increased attention going forward.  
 
Stroke and the Gut Microbiota 
The gastrointestinal (GI) tract contains a large and complex immune subsystem 9. Several 
mechanisms allow elements of the gut-associated immune system to relay diverse signals 
from commensal bacteria to the host. In this way, the gut microbiota plays a key role in the 
immune system, both in terms of its maturation and subsequent homeostasis. Recently, the 
relationship between the gut microbiota and the brain has been better elucidated. Studies have 
shown, for instance, a link between commensal bacteria and autoimmune conditions in the 
CNS 18. Importantly, dysbiosis of the gut microbiota could impact acute brain injuries such as 
stroke. Indeed, antibiotic-induced disturbances of the intestinal flora have been shown 
preclinically to influence both post-stroke neuroinflammation and overall stroke outcome, 
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Stroke can markedly affects the composition of the intestinal microbiota, which may be 
detrimental to overall disease outcome 20. A reduction in species diversity and an overgrowth 
of certain phyla, such as Bacteroidetes, is observed after stroke. This dysbiosis is postulated 
to influence immune function through an aberration in T cell homeostasis, increased levels of 
pro-inflammatory cytokines, and migration of intestinal lymphocytes to the ischaemic brain 
20. However, given that our knowledge of the gut microbiota and to some extent stroke itself 
is still limited, there may be many more mechanisms by which the brain-gut axis affects 
disease outcome, such as the infiltration of activated intestinal monocytes into the infarct site 
in the acute phase of stroke.  
TARGETS & THERAPIES 
The next section considers the key innate and adaptive components that demonstrate potential 
as drug targets, and from this, highlights an array of plausible future stroke immunotherapies.   
 
Complement 
A wealth of evidence indicates a harmful role for the complement pathway in the pathology 
of acute ischaemic stroke. The complement system, however, also plays an important part in 
the subacute and chronic post-stroke processes of neurogenesis and repair 21. Of note, 
although expression of complement proteins was long thought to be restricted to cells of the 
immune system, it is now known that astrocytes, microglia and neurons express complement 
proteins and their receptors. The complex role of complement in stroke has confounded 
efforts to develop anti-complement stroke therapies. To date, the majority of pre-clinical 
studies have focused on the contribution of anaphylatoxins C3a and C5a to perpetuating 
ischaemia-induced neuroinflammation and neuronal death 22. Mice lacking C3a receptors, for 
example, showed reduced ischaemic injury and improved functional outcome, while similar 
results were achieved with use of a C3a receptor antagonist 23. In a separate study, C3a 
receptor antagonism suppressed T cell infiltration, promoted neuroblast formation and 
provided better histologic and functional outcomes 24. Inhibition of C5a receptor decreased 
infarct size and demonstrated an improving trend in neurological function 25. Importantly, 
stroke patients deficient in mannose-binding lectin have better outcomes 26. Increased 
complement protein deposition has also been demonstrated in the infarcted human brain. 
These findings overall corroborate the view that complement has a deleterious role in the 
early stages of AIS. However, clinical translation of this effect has been limited by concerns 
such as the requirement for high dose of inhibitor, low bioavailability, poor efficacy, and 
increased risk of post-stroke infection 21. Site-specific inhibitors such as the hybrid molecules 
sCR1 and sCR1sLex were designed to circumvent these issues. sCR1 ameliorated ischemic 
injury in mice, while sCR1-sLex further reduced infarct volume, improved neurological 
outcome, and inhibited neutrophil and platelet recruitment in mice 27. Nevertheless, sCR1 did 
not prove neuroprotective in a non-human primate model of stroke, even though it was 
administered prior to middle cerebral artery occlusion 28. Similar studies performed with 
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baboons 29. Other proposed site-targeted complement inhibitors include compounds attached 
to recombinant portions of complement receptor type 2 (CR2).  A single dose of CR2-Crry 
ameliorated brain injury and improved neurological outcome in mice without increasing the 
susceptibility to infection 30. Intravenous immunoglobulin (IVIG) reduced mortality and 
functional impairment 31. The future of complement therapy in stroke may require both 
intravenous immunoglobulin (IVIG) and cocktail of the antagonists and inhibitors described 
above. Since tPA can activate the complement pathway, these agents may also be indicated as 
an adjuvant to enhance the therapeutic window for thrombolytic therapy in the acute phase of 
the disease 32.  
Inflammatory mediators 
The pathogenic role of IL-1 has been demonstrated in rodent models of cerebral ischaemia, 
where IL-1β administration at time of reperfusion lead to increased brain oedema, whereas 
IL-1α/β double knockout mice showed reduced infarct size 33. Separate studies focused on 
IL-1R1 or its inhibitor, in which deficiency/inhibition of the former or 
overexpression/administration of the latter both improved stroke outcomes 34, 35. The 
recombinant IL-1 receptor antagonist (IL-1Ra), Anakinra, has been extensively studied in 
almost all stroke types, with a recent systematic review concluding it provides a clear 
reduction in infarct size in experimental stroke 36. Phase-II clinical trials have also proved 
intravenous Anakinra safe and well-tolerated 37. However, as the intravenous formulation is 
no longer manufactured, the effects of a subcutaneous formulation, administered twice daily 
for 72 hours after acute ischemic stroke was investigated 38. The results showed IL-1Ra 
significantly reduced plasma concentrations of IL-6 and C-reactive protein. Mediation 
analysis, however, also revealed a residual negative effect, possibly due to an interaction 
between IL-1Ra and tPA. Further experimental studies are therefore required to determine 
whether therapies targeting IL-1 can be safely used in conjunction with thrombolysis.  
TNF-α is produced within the first hour after stroke and the circulating levels of TNF-α are 
correlated with infarct size and neurological impairment, while inhibition of TNF-α protects 
against ischaemic brain injury 7. TNF-α works in synergy with IL-1β, though it seems to 
mediate neuroprotective as well as neurotoxic functions. TNF-α receptor-deficient mice, for 
example, showed increased infarct volume, whereas pre-ischaemic treatment with TNF-α 
appeared to induce tolerance and reduce ischaemic injury 39, 40. The action of TNF-α may 
depend on both location and timing; higher levels in the striatum, for instance, led to 
neurodegeneration, whereas release in the hippocampus led to neuroprotection 41. Further 
studies highlight gene polymorphism, receptor subtypes, and cell signalling pathways as 
determinants of what response TNF-α will elicit 42, 43. In terms of treatment, several inhibitors 
of TNF-α and its receptors have been studied, albeit in the setting of post-stroke chronic 
neurological dysfunction 44. Notably, Etanercept or its murine analogue, attenuated motor 
deficits in both human stroke and a rodent model of traumatic brain injury 44. To date 
however, no human trials of Etanercept in acute ischaemic stroke have been published. Thus, 
both the efficacy of TNF-α therapies and the possibility that these agents might exacerbate 
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Chemokine molecules seem to play a detrimental role in the early stages of ischaemia. CCL5 
knockout mice, for example, showed smaller infarct size, while inhibition of CXCL8 offered 
neuroprotection in transient brain ischaemia 45, 46. Similarly, overexpression of CCL2 
exacerbated brain injury, most likely due to increased immune cell recruitment and 
infiltration at the ischaemic site 47. However, evidence has emerged which points to a second, 
neuroprotective function for chemokines, possibly due to the increased recruitment of stem 
cells after ischaemic insult 48. Several therapeutic approaches have been proposed in AIS 
including modified chemokines, small molecule receptor antagonists, neutralising antibodies, 
and pathogen-derived receptor antagonists 49. A number of these approaches have 
demonstrated promise. Use of the pan-chemokine specific inhibitor NR58–3.14.3, for 
example, reduced infarct size, attenuated the post-ischaemic inflammatory response, and 
improved neurological outcome in rats when infused over a 72-hour period 50. Separately, 
antibodies directed against CXCL8/CCL2 improved experimental stroke outcome by 
reducing brain oedema and BBB permeability respectively 49. In comparison to other stroke 
immunotherapies, the clinical translation of approaches targeting chemokines may be far off, 
with issues such as timing of administration and drug concentration still yet to be addressed. 
In particular, the risk of blanket chemokine inhibition on the recruitment of neuroprotective 
immune cells (e.g. M2 skewed macrophages) has yet to be resolved. Even so, drugs such as 
JWH-133 have achieved some form of selective response. The synthetic cannabinoid 2 
receptor agonist, inhibits CXCL2-mediated neutrophil recruitment to the CNS without 
compromising response in the periphery 49. This lack of systemic modulation may be 
particularly beneficial, given the SIDS-induced mortality from post-stroke infections.  
Matrix metalloproteinases (MMPs) become dysregulated in ischaemic stroke, resulting in 
neurovascular disruption and parenchymal destruction. Several MMPs, including MMP-2, 
MMP-3, and MMP-9, have been implicated in BBB degradation and infarct growth 6. In 
particular MMP-9, which is upregulated 15-48 hours after stroke, has been linked to disease 
pathology, with higher serum levels a predictor of poorer outcome 51. Data from knockout 
mouse models and pharmacological experiments demonstrated the deleterious role of MMPs 
in acute stroke and the reduction in ischemic damage that can be achieved with MMP-
targeted treatments 52. Further evidence however, suggests that MMPs also contribute to 
neurovascular remodelling and neurovasculogenesis 53. Due to this biphasic response, it is 
possible that future MMP inhibitors (such as a recombinant form of the natural inhibitor, 
TIMP-1) might only be used short-term post-stroke, so as not to interfere with angiogenesis. 
MMP inhibition might also be clinically relevant in the context of thrombolysis, as levels of 
MMP-9 are known to be elevated in response to tPA administration. In fact, it is believed that 
the interaction between tPA and MMP-9 is responsible for the phenomenon of haemorrhagic 
transformation; therefore, drugs which inhibit MMP-9 activity (e.g. minocycline) might be 
used clinically as a combination therapy with tPA in order to improve patient safety and 
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Adhesion molecules 
E- and P-selectin have been implicated in particular in leukocyte recruitment, promoting 
neuroinflammatory responses and ischaemic injury in the early phases of the disease 10. 
Selective blockade of E- or P-selectin is associated with improved neurological outcomes in 
experimental stroke 55. In contrast, an anti-L-selectin antibody did not reduce infarct volume 
or neutrophil infiltration in a rabbit model of transient focal cerebral ischaemia 56. At the level 
of clinical translation, an ongoing clinical trial is investigating the use of intranasal E-selectin 
in the secondary prevention of stroke. Such a therapy, which relies on the induction of 
tolerance to the inflammatory response following cerebral ischaemia, may yet offer a way 
forward for selectin-based treatments 57.  
Several in vitro and human studies have demonstrated an increased production of ICAM-1 
following ischaemia 58. Expression levels of this adhesion molecule increase within hours 
after the onset of ischaemia and peak 12-48 hours later, making them a suitable target in the 
acute phase. Indeed, ICAM-1 knockout mice showed reduced infarct size, decreased 
neurological deficit, and improved cerebral blood flow 59. Several other studies which 
employed ICAM-1 deficiency/blockade confirmed a reduction in ischaemic damage and 
leukocyte infiltration 60, 61. Disappointingly however, results of a phase III clinical trial 
involving anti-ICAM-1 antibody enlimomab showed poorer stroke outcomes and higher 
mortality, possibly as a result of increased neutrophilic activity 62. Retrospectively, pro-
inflammatory responses seen in enlimomab-treated patients have been attributed to the 
antigenicity of this murine antibody. As a result, a more definitive verdict on the future of 
anti-ICAM-1 immunotherapy has been postponed until humanized antibodies are tested.   
Future adhesion molecule-based therapies may also target the integrin molecules expressed 
by leukocytes as well as activated endothelium. Such molecules include leukocyte function-
associated antigen-1 (LFA-1), very late adhesion molecule-4 (VLA-4), and Mac-1 58. 
Experimental studies of Mac-1 blockade or Mac-1/LFA-1 deficiency showed benefits such as 
reductions in infarct volume, neurological deficit, and leukocyte adhesion/infiltration 63. 
Natalizumab, an anti-VLA-4 antibody used to attenuate neuroinflammation in multiple 
sclerosis (MS), reduced brain damage and improved clinical outcomes in experimental stroke 
64. Recent results of the phase II clinical trial “ACTION” however, failed to show a reduction 
in infarct growth, although improvements in functional outcomes warranted further 
investigation 65. Disappointingly, the follow-up phase IIb trial (“ACTION2”) did not meet its 
primary or secondary endpoints. As a result, further development of natalizumab in acute 
ischaemic stroke will not be pursued.  
 
Immune cells 
Typically, neutrophils are thought of as the “first responders” to stroke, with infiltration 
starting within 30 minutes of the onset of ischaemia and peaking 1-3 days later 5. However, 
despite the demonstration of deleterious mechanisms (e.g. capillary sludging, neutrophil 
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on infarct size 66. Furthermore, treatments which should reduce neutrophil infiltration, such as 
neutrophil inhibitory factor, failed to improve stroke outcomes in human clinical trials 67. One 
possible reason for the discrepancy between the original hypothesis and the negative clinical 
outcomes is the ability of neutrophils to polarise from a pro-inflammatory “N1” phenotype to 
an anti-inflammatory “N2” phenotype in response to local cytokine signalling. This 
phenomenon, similar to the theory of classically (M1) or alternatively-activated (M2) 
macrophages, can be pharmacologically manipulated with drugs such as rosiglitazone 68. 
Therefore, a better understanding of the functional significance of the N1/N2 ratio could 
increase the viability of neutrophils as a target in the future. It could be argued however, that 
due to the limited applicability of neutrophil-based therapies to the acute phase, research into 
stroke immunotherapies should instead focus on targets that contribute to the later stages of 
stroke pathophysiology. 
Resident microglia become activated within minutes of the onset of ischaemia, reaching peak 
levels within 2 days 7. Conversely the levels of monocytes/macrophages, which infiltrate 
from the peripheral circulation 1-2 days later, peak between days 3 and 7. Overall, the 
importance of local microglia activity supersedes that of monocytes/macrophages in the early 
phases of acute ischaemic stroke, though the blood-derived cells may mediate further brain 
injury in the latter stages of post-stroke neuroinflammation 7. The effect of microglia and 
monocytes/macrophages in stroke depends on the M1/M2 polarization status. It is believed 
that the anti-inflammatory M2 gives way to the pro-inflammatory M1 subtype during disease 
progression 9.  Polarisation to either phenotype is associated with the presence of specific 
cytokines in the local milieu (i.e. M1: IFN-γ, M2: TGF-β, IL-10) (Figure 1). Treatments 
which impair microglial activation, such as the free radical scavenger, edaravone, or 
hyperbaric oxygen, were shown to be neuroprotective, suggesting a detrimental role of 
microglia/macrophages in stroke 69, 70. Minocycline, a semisynthetic second-generation 
tetracycline also known to act via inhibition of microglial activity, proved effective in several 
experimental stroke models 71. An open-label placebo-controlled clinical trial found treatment 
with minocycline significantly improved clinical outcome 72. A subsequent pilot study 
however, concluded intravenous minocycline was safe but not efficacious, but pointed to the 
need for larger studies 73. Yet, separate pre-clinical studies, in which blocking macrophage 
infiltration led to undesirable outcomes such as increased haemorrhagic transformation or 
worsened long-term behavioural recovery, imply a protective effect for these cells 74. In some 
studies, inhibition of microglial activation also increased infarct size, again indicating a 
neuroprotective role 75. Evidently, a more nuanced understanding of the transitions between 
M1 and M2 phenotypes in stroke and a greater appreciation of the differences between 
resident microglia and infiltrating monocytes/macrophages is needed to warrant further 
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T cells 
γδ T cells are predominantly thought to have deleterious effects in stroke. Depletion of γδ T 
cells significantly reduced cerebral ischaemia-reperfusion (I/R) injury in an experimental 
model of stroke 76. The same study found that IL-17 was responsible for the negative impact 
of γδ T cells on infarct size and neurological function. A separate study demonstrated that, 
not only are γδ T cells the principal source of IL-17 in the ischaemic brain, but blockade of 
the IL-17 axis improved stroke outcome through reduced neutrophil invasion 77. Increased 
production of IFN-γ and perforin by γδ T cells, on the other hand, correlated positively with 
clinical improvement, possibly due to increased protection against infection 8.  Thus, future 
therapies aimed at γδ T cells must counteract the detrimental effects of secreted IL-17 
without compromising the ability to prevent infection. Furthermore, the exact crosstalk 
between stroke and the gut microbiota would have to be further elucidated, considering the 
role of γδ T cells and IL-17 in the brain-gut axis 19.  
Cytotoxic cells such as CD8+ T cells, NK T cells and NK cells are known to exacerbate 
stroke pathology. CD8+ T cells accumulate in the pan-necrotic area of the ischaemic brain as 
early as three hours post-stroke, where they mediate many cytotoxic responses, partly through 
perforin 10. However, NKT cells have garnered interest not for their neurotoxic roles, but for 
their importance in host immune function 78. It has been shown that stroke can induce 
behavioural changes in hepatic invariant NKT (iNKT) cells to an anti-inflammatory 
phenotype that facilitates infection 79. These changes, brought about by noradrenergic 
neurotransmitters, can be experimentally reversed through administration of propranolol. 
Similar results can be achieved through the activation of iNKT cells with α-
galactosylceramide, demonstrating a possible method of infection control in stroke patients. 
Such therapies would be an attractive alternative to antibiotics, but concerns remain as to 
whether the drugs could influence cerebral blood flow, or even promote inflammatory 
responses at the infarct site. Indeed, in a recent clinical study, beta-blockers did not reduce 
patient risk for post-stroke pneumonia, but did lead to higher 30-day mortality 80, highlighting 
the need for further study.  
CD4+ T cells are also recruited to the ischaemic hemisphere, in even greater numbers than 
their CD8+ counterparts 10.  In stroke, infiltrating CD4+ cells are predominantly of the Th1 
type, while peripherally Th17 cells may also contribute to ischaemic injury 81. Adoptive 
transfer of Th1 or Th17 CD4+ cells worsened behavioural outcomes in an experimental 
model of ischaemic stroke 82. Systemic treatments that promoted the Th2 phenotype on the 
other hand, e.g. IL-33, were beneficial 83. Autoimmune CD4+ cells are also implicated in 
stroke damage. The number of myelin basic protein (MBP)-responsive Th1 cells, for 
example, act as a marker for poor clinical outcome 84. The fact that many stroke patients 
display increased concentrations of CNS antigens in lymph nodes, and increased circulating 
levels of T cells specific for them, strongly indicates the presence of a self-directed immune 
response 17. Studies have also shown immunization with myelin antigens worsened outcomes 
in experimental stroke, while systemic inflammation helps prime such deleterious 
autoimmune responses 84, 85. The production of IL-4 or brain-derived neurotrophic factor 
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phenotype in myeloid cells 86. Thus, therapies which could alter the CD4+ phenotype towards 
a Th2-dominant phenotype could, in theory, be favourable. There has been some success in 
inducing tolerance to CNS antigens. Intranasal or oral application of MBP weeks before 
stroke onset reduced infarct volume and improved recovery in rats 87 while separately 
intranasal MBP administration ameliorated the Th1 response 88. Further studies however, cast 
doubt over the long-term involvement of autoreactive T cell responses in stroke, while the 
safety of induced mucosal tolerance has also been called into question 89. As a result, 
therapies which instead target T cell infiltration have received increased interest. A wealth of 
experimental data now supports the use of fingolimod in ischaemic stroke. In a mouse model 
of transient ischaemia, fingolimod reduced infarct size, neurological deficit, and 
inflammation (with fewer activated leukocytes and expression of ICAM-1 on affected blood 
vessels) 90. This sphingosine 1-phosphate receptor modulator, used for the treatment of 
relapsing-remitting MS, may prevent lymphocyte trafficking into the CNS. Further 
mechanisms of action may include suppression of reperfusion injury, direct neuroprotection 
and reduced microthrombosis 90. Recent small-scale clinical trials with ischemic or 
haemorrhagic stroke patients have shown promising effects on functional recovery 90; 
h94owever, while fingolimod remains one of the most compelling stroke immunotherapies to 
date, further large-scale clinical trials are required.   
Generally, CD4+ regulatory T cells (Treg), are believed to be neuroprotective in stroke, with 
the only detrimental effects thought to be a role in secondary microthrombosis 91. 
Approximately 20% of all CD4+ T cells found in the ischaemic hemisphere are regulatory T 
cells (Treg) 91. Treg cells, whose circulating levels increase following the onset of ischaemia, 
reduce systemic inflammatory responses but also ameliorate stroke-induced 
immunosuppression by correcting lymphopenia 92. In addition to Treg-produced IL-10, 
secondary mechanisms of Treg-mediated neuroprotection may include TGF-β and IL-35 
production, priming of M2 macrophages, reduced inflammatory cytokine secretion, etc 91. 
The increased infarct volume seen in experimental models of Treg depletion support a 
protective function in stroke, although not all studies agree 93, 94. Several studies which 
instead focused on Treg expansion (e.g. via adoptive transfer, or using CD28 super agonist) 
generally demonstrate a beneficial role of Treg in stroke 95, 96. Reasons for this inconsistency 
in experimental/clinical models may include differences in infarct size, microthrombosis, and 
variation of the local inflammatory milieu. Nevertheless, with newer studies pointing to 
involvement of Treg in both the brain-gut axis and protection against tPA-mediated 
haemorrhagic transformation, there is scope for future Treg-targeted immunotherapies 19, 97. 
 
B cells 
B cells provide both beneficial and detrimental functions in experimental and human stroke. 
The deleterious effects are suggested to be mediated through B cell derived 
immunoglobulins, which have been found in the cerebrospinal fluid of stroke patients 13. 
These brain-antigen specific antibodies may be involved in late-phase chronic inflammatory 
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alone did not display neuroprotection 12. A separate study reported that B cell deficiency 
itself leads to worsened stroke outcomes 13. The same study highlighted that adoptive transfer 
of B cells can ameliorate neurological deficits and reduce lesion size. Regulatory B cells 
(Bregs), which secrete the anti-inflammatory cytokine IL-10, were proposed to be responsible 
for this neuroprotective effect 99. In summary, B cells appear to have a conflicting role in 
stroke, with the positive effects of IL-10 on the local inflammatory milieu counterbalanced by 
the negative effect of antibodies secreted from differentiated B cells. As in the case of T cells, 
future stroke immunotherapy will therefore rely on enhancing the regulatory phenotype 
(fingolimod, glatiramer acetate) 13. The B-cell depleting antibody, anti-CD20, has received 
increased interest in stroke research for its apparent ability to ameliorate antibody-induced 
long-term cognitive impairment. In a mouse study, anti-CD20 IV injection every 2 weeks, 
beginning 5 days post-stroke, prevented B cell and IgG recruitment to the infarct site, and 
prevented the appearance of delayed cognitive deficits 98. As rituximab is already well-
characterised and approved for use in another CNS disorder (MS), anti-CD20 may well be 
the next immunomodulatory therapy to progress to trial in AIS. 
 
Antibiotics/ brain-gut axis 
To date, the clinical trial results of various antibacterial agents in stroke have not been 
encouraging. Despite significant reductions in the risk of overall post-stroke infection 
(notably, the risk of pneumonia remains unchanged), a recent systematic review concluded 
preventative antibiotics have no effect on functional outcome or mortality in stroke 100. Some 
researchers have argued this may relate to the individual antibiotics tested, as the 
fluoroquinolone class in particular display neurotoxic properties, whereas ceftriaxone, a 
cephalosporin, offers neuroprotection. In a small randomized controlled trial, the combined 
administration of mezlocillin and sulbactam did lead to improved clinical outcomes 100 . 
Future research may therefore rely on identifying both the correct antibiotic regimen and 
patient cohort (e.g. through blood-based biomarkers, risk scoring models) most likely to 
benefit from prophylactic therapy. 
Recently, interest in the gut microbiota and the brain-gut axis has extended from a role in 
stroke pathology to a possible place in stroke treatment. One study considered the use of 
faecal microbiota transplant (FMT) therapy. Mice which received FMT showed normalised 
gut flora and improved stroke outcome, suggesting an exciting future for such novel therapies 
20.  
CONCLUSION 
Over the past several decades, a broad picture of the immune response to stroke has emerged. 
A host of innate and adaptive immune components have been implicated in both ischaemic 
injury and post-stroke repair (Figure 2). Thus, it is now widely accepted that many elements 
of the immune system have multi-faceted roles in stroke, often switching between beneficial 
and detrimental phenotypes. Functional polarisation occurs as a result of local or systemic 
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immunity, coupled to the phenomenon of stroke-induced immunosuppression, will have to be 
taken into consideration to develop effective stroke therapies. 
Many of the drugs trialled to date target the innate immune response to stroke. Thus, their use 
would be restricted to the acute phase of the disease, a caveat which, similar to tPA, would 
limit widespread clinical use. Conversely, therapies modulating the adaptive immune 
response to stroke (fingolimod, rituximab, natalizumab, Treg/Breg-based therapies) could 
feasibly be used across a timescale of days to weeks post-stroke, lending them greater clinical 
promise. Separately, the development of drugs which could bolster the host defence against 
post-stroke infection has become increasingly important in the era of antibiotic resistance.  
Ultimately, the usefulness of immunomodulatory drugs for stroke treatment will depend on 
greater knowledge of how the intimate, bi-directional communication between the CNS and 
the immune system changes with disease progression. Likewise, an increased understanding 
of the time-sensitive nature of many immune targets should lead to better translation from 
bench to bedside in the years to come. However, while time is the most obvious factor to take 
into consideration, patient comorbidities and pre-existing conditions are also likely to be 
important predictors of immunomodulatory drug efficacy. Hypertension, hyperlipidemia, 
diabetes (to name a few important stroke risk factors) are all associated with a pro-
inflammatory phenotype, but most preclinical studies are performed in healthy young mice. 
Changes are therefore needed at both the preclinical stage, so that candidate drugs are tested 
in animal models with the relevant comorbidities, and at the clinical level, where patients 
may have to be stratified based on their individual inflammatory/immune status as assessed 
by specific markers. This patient-specific phenotype may ultimately be a more important 
predictor of efficacy than time alone. 
The ever-growing list of immunomodulatory drugs approved for other indications which now 
show potential as therapies in stroke may also provide an opportunity to fast-track future 
trials. Care, however, must be taken to avoid the pitfalls of past trials, where candidate 
therapies were put forward without sufficient experimental evidence in support 4. 
Appreciation must also be given to the overall immune response to stroke, and the untoward 
ramifications which could occur from manipulating even a single target. Despite such 
limitations, the possible advantages of immunotherapy over other candidate drugs in stroke 
continues to attract greater interest. With applications ranging from reduced post-stroke 
infection, to improved functional outcomes, to better cognitive recovery, drugs targeting the 
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Figure Legends 
Figure 1: The effect of the inflammatory milieu on immune cell function in stroke. The 
balance between pro- and anti-inflammatory cytokines influences the differentiation of 
activated microglia and leukocytes into neuroprotective (left) or harmful (right) phenotypes. 
(*Adapted from Servier Medical Art) 
Figure 2: A time course of immune targets in stroke. Targets are placed according to the 
predominant role each plays in either neurotoxicity (red) or tissue remodelling and repair 
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